Tania Vásquez Loarte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tania Vásquez Loarte has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Felix Chavesta Velásquez
Instituto Nacional de Salud del Niño-Breña
2 shared publications - Heinner Guio
Laboratorio de Innovación y Desarrollo, Instituto Nacional de Salud, Lima, Perú.
2 shared publications - Hugo Hernán Abarca-Barriga
Universidad Ricardo Palma
2 shared publications - Abel Paucarmayta Tacuri
Universidad Nacional de San Antonio Abad del Cusco
1 shared publication - Alberto Mendoza-Ticona
Socios en Salud , Lima
1 shared publication - Alonso Soto
Instituto de Investigaciones en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú
1 shared publication
Latest Publications
- Open Access
- 28 October 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-9
Healthcare access satisfaction before and during the COVID-19 pandemic among Peruvian children with down syndrome
Background: In Peru, more than 9,000 individuals with Down syndrome (DS) experienced disruptions in healthcare access due to strict limitations on appointment availability and widespread hospital and clinic closures during the COVID-19 pandemic. This study examines changes in parental satisfaction with healthcare access before and during the pandemic (2021 vs. 2019), as reported by caregivers of children with DS. Methods: We conducted a cross-sectional survey between October 2022 and April 2023 among parents of children with DS, aged 2–12 years, affiliated with the Peruvian Association for Children with Down Syndrome. The survey collected information on family demographics, comorbidities, medical care, and satisfaction with healthcare access. The primary outcome was the change in parental satisfaction between 2019 and 2021. The secondary outcome assessed healthcare utilization. Linear regression analysis was used to evaluate associations between healthcare utilization and satisfaction, adjusting for type of disability, parental education level, and type of health insurance. Results: A total of 223 participants were included in the analysis. Developmental delay (75%) and cardiac conditions (41%) were the most commonly reported comorbidities. In 2019, 68.2% of children ( n = 152) attended at least one medical appointment, compared to 53.8% ( n = 120) in 2021. Among children with visits in both years ( n = 72), satisfaction with healthcare access declined by 10.9 points (95% CI: 4.8–16.9; p < 0.01). For those receiving pediatric care during both years ( n = 43), satisfaction decreased by 11.8 points (95% CI: 3.4–20.1; p < 0.01). In 2021, all specialties except pediatrics showed a discrepancy between needed and received care, with early intervention services showing the largest gap. Conclusions: The COVID-19 emergency significantly impacted healthcare access satisfaction among children with DS. Strengthening pediatric training in genetic conditions is critical, particularly in low-resource settings where access to specialists is limited.
- 28 October 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-9
Open AccessHealthcare access satisfaction before and during the COVID-19 pandemic among Peruvian children with down syndrome
Background: In Peru, more than 9,000 individuals with Down syndrome (DS) experienced disruptions in healthcare access due to strict limitations on appointment availability and widespread hospital and clinic closures during the COVID-19 pandemic. This study examines changes in parental satisfaction with healthcare access before and during the pandemic (2021 vs. 2019), as reported by caregivers of children with DS. Methods: We conducted a cross-sectional survey between October 2022 and April 2023 among parents of children with DS, aged 2–12 years, affiliated with the Peruvian Association for Children with Down Syndrome. The survey collected information on family demographics, comorbidities, medical care, and satisfaction with healthcare access. The primary outcome was the change in parental satisfaction between 2019 and 2021. The secondary outcome assessed healthcare utilization. Linear regression analysis was used to evaluate associations between healthcare utilization and satisfaction, adjusting for type of disability, parental education level, and type of health insurance. Results: A total of 223 participants were included in the analysis. Developmental delay (75%) and cardiac conditions (41%) were the most commonly reported comorbidities. In 2019, 68.2% of children ( n = 152) attended at least one medical appointment, compared to 53.8% ( n = 120) in 2021. Among children with visits in both years ( n = 72), satisfaction with healthcare access declined by 10.9 points (95% CI: 4.8–16.9; p < 0.01). For those receiving pediatric care during both years ( n = 43), satisfaction decreased by 11.8 points (95% CI: 3.4–20.1; p < 0.01). In 2021, all specialties except pediatrics showed a discrepancy between needed and received care, with early intervention services showing the largest gap. Conclusions: The COVID-19 emergency significantly impacted healthcare access satisfaction among children with DS. Strengthening pediatric training in genetic conditions is critical, particularly in low-resource settings where access to specialists is limited.
- 2 February 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 44 (3) , 373-378
A new algorithm DEtectS critical Congenital Heart Disease at different altitudes: ANDES-CHD study
Background Neonatal pulse oximetry screening (POS) algorithms for critical congenital heart disease (CCHD) have contributed towards decreasing neonatal mortality but cannot be applied at high altitudes. New POS algorithms at high altitudes are needed. Methods This observational, prospective study included newborns born at different altitudes from 0 to 4380 meters above the sea level in Peru. Healthy newborns underwent neonatal preductal and postductal oximetry, echocardiography and telephonic follow-up up to 12 months of age. Newborns with CCHD underwent preductal and postductal oximetry at the time of telemedicine evaluation while located at the high-altitude hospital where they were born, and their diagnoses were confirmed with echocardiography locally or after arriving to the referral center. Two new algorithms were designed using clinically accepted neonatal oximetry cutoffs or the 5th and 10th percentiles for preductal and postductal oximetry values. Results A total of 502 healthy newborns and 15 newborns with CCHD were enrolled. Echocardiography and telephonic follow-up were completed in 227 (45%) and 330 healthy newborns (65%), respectively. The algorithm based on clinically accepted cutoffs had a sensitivity of 92%, specificity of 73% and false positive rate of 27% The algorithm based on the 5th and 10th percentiles had a sensitivity of 80%, specificity of 88% and false positive rate of 12%. Conclusions Two algorithms that detect CCHD at different altitudes had adequate performance but high false positive rates.
- 2 February 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 44 (3) , 373-378
A new algorithm DEtectS critical Congenital Heart Disease at different altitudes: ANDES-CHD study
Background Neonatal pulse oximetry screening (POS) algorithms for critical congenital heart disease (CCHD) have contributed towards decreasing neonatal mortality but cannot be applied at high altitudes. New POS algorithms at high altitudes are needed. Methods This observational, prospective study included newborns born at different altitudes from 0 to 4380 meters above the sea level in Peru. Healthy newborns underwent neonatal preductal and postductal oximetry, echocardiography and telephonic follow-up up to 12 months of age. Newborns with CCHD underwent preductal and postductal oximetry at the time of telemedicine evaluation while located at the high-altitude hospital where they were born, and their diagnoses were confirmed with echocardiography locally or after arriving to the referral center. Two new algorithms were designed using clinically accepted neonatal oximetry cutoffs or the 5th and 10th percentiles for preductal and postductal oximetry values. Results A total of 502 healthy newborns and 15 newborns with CCHD were enrolled. Echocardiography and telephonic follow-up were completed in 227 (45%) and 330 healthy newborns (65%), respectively. The algorithm based on clinically accepted cutoffs had a sensitivity of 92%, specificity of 73% and false positive rate of 27% The algorithm based on the 5th and 10th percentiles had a sensitivity of 80%, specificity of 88% and false positive rate of 12%. Conclusions Two algorithms that detect CCHD at different altitudes had adequate performance but high false positive rates.
- Open Access
- 30 March 2023
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 4 (1) , 7-12
The SYNTAX Revascularization Index and major cardiovascular events in patients with multivessel coronary artery disease in the Instituto Nacional de Cardiología Ignacio Chávez – Mexico
Objective. To evaluate the degree of incomplete revascularization in patients with multiarterial coronary artery disease who underwent percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) using the Syntax revascularization index (SRI) and its relationship to major cardiovascular events during follow-up. Materials and Methods. Observational, retrospective study with 4-year follow-up of patients with multiarterial coronary artery disease who underwent surgical or percutaneous coronary revascularization, in whom the baseline Syntax score (SSb) and the residualSyntax score (SSr) were calculated. The Syntax Revascularization Index (SRI) was determined withthe following formula: SRI = (1- [SSr/SSb]) x 100, and major cardiovascular events at 4-year follow-up were compared. Results. Two hundred patients (100 in each group) were evaluated. Mean SSr in group 1 was 83.2%, and in group 2, 79.0% (p=0.88). Mean complete revascularization was 41% in the first group and 35% in the second. A cutoff point of ≤90% of IRS had the best accuracy for predicting major cardiovascular events (area under the curve of 0.60; 95% CI: 0.49-0.71, p<0.05). In multivariate analysis IRS was an independent predictor of major cardiovascular events (HR 2.6; 95%CI: 1.32-3.22, p= 0.043). Conclusions. The Syntax Revascularization Index may be useful for measuring the degree of revascularization in patients with multiarterial coronary artery disease treated percutaneously or surgically. An SRI ≥90% may be an acceptable target for revascularization.
- 30 March 2023
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 4 (1) , 7-12
Open AccessThe SYNTAX Revascularization Index and major cardiovascular events in patients with multivessel coronary artery disease in the Instituto Nacional de Cardiología Ignacio Chávez – Mexico
Objective. To evaluate the degree of incomplete revascularization in patients with multiarterial coronary artery disease who underwent percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) using the Syntax revascularization index (SRI) and its relationship to major cardiovascular events during follow-up. Materials and Methods. Observational, retrospective study with 4-year follow-up of patients with multiarterial coronary artery disease who underwent surgical or percutaneous coronary revascularization, in whom the baseline Syntax score (SSb) and the residualSyntax score (SSr) were calculated. The Syntax Revascularization Index (SRI) was determined withthe following formula: SRI = (1- [SSr/SSb]) x 100, and major cardiovascular events at 4-year follow-up were compared. Results. Two hundred patients (100 in each group) were evaluated. Mean SSr in group 1 was 83.2%, and in group 2, 79.0% (p=0.88). Mean complete revascularization was 41% in the first group and 35% in the second. A cutoff point of ≤90% of IRS had the best accuracy for predicting major cardiovascular events (area under the curve of 0.60; 95% CI: 0.49-0.71, p<0.05). In multivariate analysis IRS was an independent predictor of major cardiovascular events (HR 2.6; 95%CI: 1.32-3.22, p= 0.043). Conclusions. The Syntax Revascularization Index may be useful for measuring the degree of revascularization in patients with multiarterial coronary artery disease treated percutaneously or surgically. An SRI ≥90% may be an acceptable target for revascularization.
- Open Access
- 6 June 2022
- Published by Universidad Nacional de Córdoba in Revista de la Facultad de Ciencias Médicas de Córdoba
- Vol. 79 (2) , 132-140
Variantes en el número de copias y consanguinidad parental en neonatos de altura con anomalías congénitas en Perú
Introducción. Las variantes en el número de copias son un tipo de cambios en el genoma provocan anomalías congénitas. Objetivo. Determinar las variantes en el número de copias y el grado de consanguinidad parental en neonatos con síndromes malformativos o una anomalía congénita mayor asociado a dismorfia facial o hipotonía. Material y métodos. Se realizó el análisis cromosómico por micromatrices a 60 neonatos con anomalías congénitas evaluados en los Hospitales Antonio Lorena y Regional de Cusco. Resultados. Del total de pacientes estudiados, el 70% tuvo un resultado anómalo; de los cuales en el 14,2% de los recién nacidos se encontraron variantes en el número de copias patogénicas o probablemente patogénicas asociadas o no a regiones de homocigosidad que tuvieron relación con las anomalías congénitas descritas. En el 48,3% de los recién se encontró regiones de homocigosidad mayores a 0,5% (coeficiente de endogamia superior a 1/64). Por otro lado, encontramos cinco variantes en el número de copias de patogenicidad desconocida que no se han descrito anteriormente y podrían estar relacionadas con el fenotipo. Conclusiones. Nuestra tasa de detección de las variantes en el número de copias está en relación con los reportes internacionales previos. Sin embargo, el porcentaje de neonatos con consanguinidad parental se encuentra por encima de lo reportado previamente, siendo superior a otras regiones de Sudamerica. Este es el primer reporte en el Perú, y es pionero en Latinoamérica al utilizar el análisis cromosómico por micromatrices en esta cohorte específica de pacientes.
- 6 June 2022
- Published by Universidad Nacional de Córdoba in Revista de la Facultad de Ciencias Médicas de Córdoba
- Vol. 79 (2) , 132-140
Open AccessVariantes en el número de copias y consanguinidad parental en neonatos de altura con anomalías congénitas en Perú
Introducción. Las variantes en el número de copias son un tipo de cambios en el genoma provocan anomalías congénitas. Objetivo. Determinar las variantes en el número de copias y el grado de consanguinidad parental en neonatos con síndromes malformativos o una anomalía congénita mayor asociado a dismorfia facial o hipotonía. Material y métodos. Se realizó el análisis cromosómico por micromatrices a 60 neonatos con anomalías congénitas evaluados en los Hospitales Antonio Lorena y Regional de Cusco. Resultados. Del total de pacientes estudiados, el 70% tuvo un resultado anómalo; de los cuales en el 14,2% de los recién nacidos se encontraron variantes en el número de copias patogénicas o probablemente patogénicas asociadas o no a regiones de homocigosidad que tuvieron relación con las anomalías congénitas descritas. En el 48,3% de los recién se encontró regiones de homocigosidad mayores a 0,5% (coeficiente de endogamia superior a 1/64). Por otro lado, encontramos cinco variantes en el número de copias de patogenicidad desconocida que no se han descrito anteriormente y podrían estar relacionadas con el fenotipo. Conclusiones. Nuestra tasa de detección de las variantes en el número de copias está en relación con los reportes internacionales previos. Sin embargo, el porcentaje de neonatos con consanguinidad parental se encuentra por encima de lo reportado previamente, siendo superior a otras regiones de Sudamerica. Este es el primer reporte en el Perú, y es pionero en Latinoamérica al utilizar el análisis cromosómico por micromatrices en esta cohorte específica de pacientes.
- Open Access
- 12 September 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (10) , e1764
Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients
Background: We determined the frequency of genetic polymorphisms in three anti‐TB drug metabolic proteins previously reported: N‐acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1), and arylacetamide deacetylase (AADAC) within a Peruvian population in a cohort of TB patients.Methods: We genotyped SNPs rs1041983, rs1801280, rs1799929, rs1799930, rs1208, and rs1799931 for NAT2; rs3813867 and rs2031920 for CYP2E1; and rs1803155 for AADAC in 395 participants completed their antituberculosis treatment.Results: Seventy‐four percent of the participants are carriers of slow metabolizer genotypes: NAT2*5, NAT2*6, and NAT2*7, which increase the sensitivity of INH at low doses and increase the risk of drug‐induced liver injuries. Sixty‐four percent are homozygous for the wild‐type CYP2E1*1A allele, which could increase the risk of hepatotoxicity. However, 16% had a NAT2 fast metabolizer phenotype which could increase the risk of acquiring resistance to INH, thereby increasing the risk of multidrug‐resistant (MDR) or treatment failure. The frequency of rs1803155 (AADAC*2 allele) was higher (99.9%) in Peruvians than in European American, African American, Japanese, and Korean populations.Conclusions: This high prevalence of slow metabolizers for isoniazid in the Peruvian population should be further studied and considered to help individualize drug regimens, especially in countries with a great genetic diversity like Peru. These data will help the Peruvian National Tuberculosis Control Program develop new strategies for therapies.
- 12 September 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (10) , e1764
Open AccessAllelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients
Background: We determined the frequency of genetic polymorphisms in three anti‐TB drug metabolic proteins previously reported: N‐acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1), and arylacetamide deacetylase (AADAC) within a Peruvian population in a cohort of TB patients.Methods: We genotyped SNPs rs1041983, rs1801280, rs1799929, rs1799930, rs1208, and rs1799931 for NAT2; rs3813867 and rs2031920 for CYP2E1; and rs1803155 for AADAC in 395 participants completed their antituberculosis treatment.Results: Seventy‐four percent of the participants are carriers of slow metabolizer genotypes: NAT2*5, NAT2*6, and NAT2*7, which increase the sensitivity of INH at low doses and increase the risk of drug‐induced liver injuries. Sixty‐four percent are homozygous for the wild‐type CYP2E1*1A allele, which could increase the risk of hepatotoxicity. However, 16% had a NAT2 fast metabolizer phenotype which could increase the risk of acquiring resistance to INH, thereby increasing the risk of multidrug‐resistant (MDR) or treatment failure. The frequency of rs1803155 (AADAC*2 allele) was higher (99.9%) in Peruvians than in European American, African American, Japanese, and Korean populations.Conclusions: This high prevalence of slow metabolizers for isoniazid in the Peruvian population should be further studied and considered to help individualize drug regimens, especially in countries with a great genetic diversity like Peru. These data will help the Peruvian National Tuberculosis Control Program develop new strategies for therapies.
- Open Access
- 8 October 2020
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4) , 77
Considering Proximal Urea Cycle Disorders in Expanded Newborn Screening
Proximal urea cycle disorders (PUCDs) have adverse outcomes such as intellectual disability and death, which may benefit from newborn screening (NBS) through early detection and prevention with early treatment. Ornithine transcarbamylase deficiency (OTCD) and carbamoyl phosphate synthetase 1 deficiency (CPS1D) are screened in six and eight states in the United States. We analyzed current evidence to see if it supports inclusion of PUCDs in the NBS panels based upon prevention potential, medical, diagnostic, treatment, and public health rationales. A literature review was performed in PubMed using MESH terms for OTCD, CPS1D, and NAGSD. A systematic review was performed in the hallmark of NBS inclusion criteria. We reviewed 31 articles. Molecular and biochemical diagnosis is available to provide diagnostic evidence. Untreated PUCDs have a significant burden with considerable developmental delay and mortality that may improve with early treatment. Tandem mass spectrometry can be used for NBS for PUCDs; however, citrulline and glutamine alone are not specific. Medical treatments currently available for PUCDs meet existing medical, diagnostic, treatment, and public health rationales. Improvement in NBS algorithms to increase sensitivity and specificity will allow earlier diagnosis and treatment to potentially improve disability and mortality rates.
- 8 October 2020
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4) , 77
Open AccessConsidering Proximal Urea Cycle Disorders in Expanded Newborn Screening
Proximal urea cycle disorders (PUCDs) have adverse outcomes such as intellectual disability and death, which may benefit from newborn screening (NBS) through early detection and prevention with early treatment. Ornithine transcarbamylase deficiency (OTCD) and carbamoyl phosphate synthetase 1 deficiency (CPS1D) are screened in six and eight states in the United States. We analyzed current evidence to see if it supports inclusion of PUCDs in the NBS panels based upon prevention potential, medical, diagnostic, treatment, and public health rationales. A literature review was performed in PubMed using MESH terms for OTCD, CPS1D, and NAGSD. A systematic review was performed in the hallmark of NBS inclusion criteria. We reviewed 31 articles. Molecular and biochemical diagnosis is available to provide diagnostic evidence. Untreated PUCDs have a significant burden with considerable developmental delay and mortality that may improve with early treatment. Tandem mass spectrometry can be used for NBS for PUCDs; however, citrulline and glutamine alone are not specific. Medical treatments currently available for PUCDs meet existing medical, diagnostic, treatment, and public health rationales. Improvement in NBS algorithms to increase sensitivity and specificity will allow earlier diagnosis and treatment to potentially improve disability and mortality rates.
- 14 May 2020
- Published by Colegio Medico del Peru in ACTA MEDICA PERUANA
- Vol. 37 (2)
Variantes en el número de copias en trastornos del neurodesarrollo, síndrome malformativo y talla baja en Perú
Objetivo: determinar las variantes en el número de copias y regiones de homocigosidad mediante el análisis cromosómico por micromatrices, en niños con diagnóstico de trastorno del neurodesarrollo: retraso del desarrollo psicomotor (RDPM), discapacidad intelectual (DI) y trastorno del espectro autista (TEA), así como pacientes con síndrome malformativo (SM) y talla baja idiopática (TBI). Materiales y métodos: se evaluaron a 367 niños peruanos diagnosticados clínicamente con DI, RDPM, TEA, TBI y SM a quienes se les realizó el análisis cromosómico por micromatrices (CMA 750K CGH+SNP) en sangre periférica, entre los años 2016-2018. Resultados: las edades fluctuaron entre los 4,8 meses y los 18 años, con una media de 5,6 años. Los diagnósticos más frecuentes fueron RDPM (48%) y DI (30%). Se reportaron resultados anormales (variantes patogénicas, probablemente patogénicas, disomías uniparentales y regiones de homocigosidad superiores a 2,56%) en el 50,3% de los pacientes. Los resultados anormales se observaron en el 53,3% de los casos con diagnóstico de DI y el 47,9% de RDPM; mientras que en el resto de los casos con TBI sindrómica, SM y TEA tuvieron resultados anormales en el 52,4%, 52% y 20% respectivamente. Por otro lado, encontramos hasta un 6,2% de los padres eran consanguíneos no declarados. Conclusiones: la tasa de detección de las variantes en el número de copias (CNVs) encontrada en nuestro estudio fue superior a la reportada en estudios internacionales independientemente del diagnóstico clínico. Además, se pudo encontrar una mayor frecuencia de consanguinidad no declarada con relación a estudios anteriores.
- 14 May 2020
- Published by Colegio Medico del Peru in ACTA MEDICA PERUANA
- Vol. 37 (2)
Variantes en el número de copias en trastornos del neurodesarrollo, síndrome malformativo y talla baja en Perú
Objetivo: determinar las variantes en el número de copias y regiones de homocigosidad mediante el análisis cromosómico por micromatrices, en niños con diagnóstico de trastorno del neurodesarrollo: retraso del desarrollo psicomotor (RDPM), discapacidad intelectual (DI) y trastorno del espectro autista (TEA), así como pacientes con síndrome malformativo (SM) y talla baja idiopática (TBI). Materiales y métodos: se evaluaron a 367 niños peruanos diagnosticados clínicamente con DI, RDPM, TEA, TBI y SM a quienes se les realizó el análisis cromosómico por micromatrices (CMA 750K CGH+SNP) en sangre periférica, entre los años 2016-2018. Resultados: las edades fluctuaron entre los 4,8 meses y los 18 años, con una media de 5,6 años. Los diagnósticos más frecuentes fueron RDPM (48%) y DI (30%). Se reportaron resultados anormales (variantes patogénicas, probablemente patogénicas, disomías uniparentales y regiones de homocigosidad superiores a 2,56%) en el 50,3% de los pacientes. Los resultados anormales se observaron en el 53,3% de los casos con diagnóstico de DI y el 47,9% de RDPM; mientras que en el resto de los casos con TBI sindrómica, SM y TEA tuvieron resultados anormales en el 52,4%, 52% y 20% respectivamente. Por otro lado, encontramos hasta un 6,2% de los padres eran consanguíneos no declarados. Conclusiones: la tasa de detección de las variantes en el número de copias (CNVs) encontrada en nuestro estudio fue superior a la reportada en estudios internacionales independientemente del diagnóstico clínico. Además, se pudo encontrar una mayor frecuencia de consanguinidad no declarada con relación a estudios anteriores.
- Open Access
- 30 October 2015
- Published by Springer Nature in BMC Genomic Data
- Vol. 16 (1) , 128
Genetic association meta-analysis: a new classification to assess ethnicity using the association of MCP-1 -2518 polymorphism and tuberculosis susceptibility as a model
In meta-analyses of genetic association studies, ancestry and ethnicity are not accurately investigated. Ethnicity is usually classified using conventional race/ethnic categories or continental groupings even though they could introduce bias increasing heterogeneity between and within studies; thus decreasing the external validity of the results. In this study, we performed a meta-analysis using a novel ethnic classification system to test the association between MCP-1 -2518 polymorphism and pulmonary tuberculosis. Our new classification considers genetic distance, migration and linguistic origins, which will increase homogeneity within ethnic groups. We included thirteen studies from three continents (Asia, Africa and Latin America) and considered seven ethnic groups (West Africa, South Africa, Saharan Africa, East Asia, South Asia, Persia and Latin America). The results were compared to the continental group classification. We found a significant association between MCP-1 -2518 polymorphism and TB susceptibility only in the East Asian and Latin American groups (OR 3.47, P = 0.08; OR 2.73, P = 0.02). This association is not observed in other ethnic groups that are usually considered in the Asian group, such as India and Persia, or in the African group. There is an association between MCP-1 -2518 polymorphism and TB susceptibility only in the East Asian and Latin American groups. We suggest the use of our new ethnic classification in future meta-analysis of genetic association studies when ancestry markers are not available. This new classification increases homogeneity for certain ethnic groups compared to the continental classification. We recommend considering previous data about migration, linguistics and genetic distance when classifying ethnicity in further studies.
- 30 October 2015
- Published by Springer Nature in BMC Genomic Data
- Vol. 16 (1) , 128
Open AccessGenetic association meta-analysis: a new classification to assess ethnicity using the association of MCP-1 -2518 polymorphism and tuberculosis susceptibility as a model
In meta-analyses of genetic association studies, ancestry and ethnicity are not accurately investigated. Ethnicity is usually classified using conventional race/ethnic categories or continental groupings even though they could introduce bias increasing heterogeneity between and within studies; thus decreasing the external validity of the results. In this study, we performed a meta-analysis using a novel ethnic classification system to test the association between MCP-1 -2518 polymorphism and pulmonary tuberculosis. Our new classification considers genetic distance, migration and linguistic origins, which will increase homogeneity within ethnic groups. We included thirteen studies from three continents (Asia, Africa and Latin America) and considered seven ethnic groups (West Africa, South Africa, Saharan Africa, East Asia, South Asia, Persia and Latin America). The results were compared to the continental group classification. We found a significant association between MCP-1 -2518 polymorphism and TB susceptibility only in the East Asian and Latin American groups (OR 3.47, P = 0.08; OR 2.73, P = 0.02). This association is not observed in other ethnic groups that are usually considered in the Asian group, such as India and Persia, or in the African group. There is an association between MCP-1 -2518 polymorphism and TB susceptibility only in the East Asian and Latin American groups. We suggest the use of our new ethnic classification in future meta-analysis of genetic association studies when ancestry markers are not available. This new classification increases homogeneity for certain ethnic groups compared to the continental classification. We recommend considering previous data about migration, linguistics and genetic distance when classifying ethnicity in further studies.